Genomics Market Size and Growth 2025 to 2034
The global genomics market size was reached at USD 37.94 billion in 2024 and is expected to be worth around USD 175.18 billion by 2034, growing at a compound annual growth rate (CAGR) of 16.53% over the forecast period 2025 to 2034. Technology, government funding, and a boom in the demand for personalized medicine have been causing an expansion of the genomics market. In recent times, improvements in NGS have reduced the time and costs associated with analyzing genomes. All governments worldwide have been investing in genomics research to improve healthcare outcomes of patients suffering from diseases like cancer and rare genetic disorders. The growing importance of precision medicine, using genetic information, to customize treatments is also fostering growth in the market. Along with that, with the trend of more incorporation of genomics in the development of drugs and prevention of diseases, it has gained much importance. Increasing public awareness about genetic testing and its benefits supports the growth. All these together make genomics a vital focus area in health care and research, propelling its fast growth.

Genomics is the scientific study of genes and their actions and interactions in living organisms, including the genetic variation that occurs within DNA related to health and disease or to aspects of biological traits. This, therefore, would include the use of DNA sequencing, gene editing, and the application of genomics bioinformatics tools in understanding genetic disorders; creating treatments adapted to an individual's genetic predisposition; agricultural improvements; and environmental sustainability. Direct-to-consumer genetic tests are becoming increasingly popular in that they educate people about their ancestry, health risks, and traits. Further, the genomics world is changing by analyzing large amounts of data through artificial intelligence and making research more rapid and quick in discovery. Governments and private organizations are funding genomics research, which gives a boost to innovation. Use of genomics in agriculture is improving crops and livestock, making it a widely applied field as well. Thus, these trends have not only changed healthcare but are also changing global challenges, with genomics acting as a fast-growing market in this regard.
- UK Government Investment: In December 2022, the UK government announced $190 million (175 million euros) for genomics research. That funding is primarily aimed at seeking better ways of diagnosing and treating cancer patients and children who suffer from rare genetic diseases. It is a part of the "Life Sciences Vision" introduced in 2021, designed to make the UK a leading country in functional genomics.
- Australian Government Commitment: The Australian Department of Health has promised $500 million over ten years for genomics research. This funding, under the Medical Research Future Fund (MRFF), will support testing, diagnosis, and treatment through genomics. It is expected to benefit over 200,000 Australians.
- CDC Pathogen Genomics Funding: In September 2022, the U.S. Centers for Disease Control and Prevention gave $90 million to the network of Pathogen Genomics Centers of Excellence. This program researches pathogens, or disease-causing organisms, as well as employing genomics and molecular epidemiology to improve health outcomes.
Genomics Market Report Highlights
- The North America has generated highest revenue share of around 42.50% in 2024.
- Europe has accounted revenue share of 27.70% in 2024.
- By study type, the functional genomics segment has held revenue share of 32.40% in 2024.
- By deliverables, products segment has recorded revenue share of 68% in 2024.
- By end-User, the pharmaceutical and biotechnology companies segment has recorded revenue share of 48% in 2024.
Genomics Market Growth Factors
- New Technologies in Genomics: Genomics is rapidly growing with next-generation sequencing technology, which provides faster and more affordable DNA sequencing. This kind of tool lets scientists analyze complicated genetic data accurately, leading to breakthroughs in personalized medicine. Automation and artificial intelligence have further pushed the boundaries in genomic research with the ability to analyze large amounts of data effectively, leading to innovation in the diagnosis and treatment of diseases.
- Rise in Demand for Personalized Medicine: Genomics is the route to personalized medicine where treatments are specifically made according to the genetic makeup of a patient. This maximizes the efficiency of treatment in such diseases as cancer and rare genetic disorders. Because of this shift toward personalized care in healthcare, genomic testing and its applications are becoming more and more in demand. Today, patients and care providers alike look for custom-made solutions that drive the market ahead.
- Increased government spending: Several such initiatives can be mentioned such as UK's Life Sciences Vision and Australia's Medical Research Future Fund, both targeted at the disease diagnosis and treatment through genomics-based diagnosis and treatment. Investments of this kind generate innovation, new applications of genomic tools, and access, thus they contribute to the overall growth of the market in a positive direction.
- Novel Drug Discovery and Development: Pharmaceutical firms use this information for the development of more effective drugs. It also aids in predicting drug responses in patients, thus reducing trial failures. That saves on research costs and improves safety for drugs and faster access to markets. Thus, genomics is critical in pharmaceutical progress. AI algorithms in genetics open up ways to find patterns and predict results, thus facilitating faster discovery. Through big data, large-scale genomic studies give more accurate insights. In this way, the process of research becomes more efficient, driving innovations forward, and thus propelling the growth of the genomics market.
- Raising awareness of genetic testing: Public awareness of the benefits of genetic testing is growing due to healthcare campaigns and advancements in direct-to-consumer genetic tests. These tests aid in understanding ancestry, disease risks, and health traits, thereby attracting more consumers. The growing accessibility and affordability of genetic testing are the primary drivers of consumer interest and, therefore, expansion in the genomics market.
Genomics Market Trends
- Rising Trend of Next-Generation Sequencing: NGS is the gold standard in genomics today. The technology helps researchers to sequence genomes quickly and inexpensively. Such a need arises in both research and healthcare industries. Its popularity is increasing since researchers apply the technology to the diagnosis diseases, customized medicine, and drug development. Its precision makes it widely adopted in any industry.
- Precision Medicine is Rising End: Precision medicine is the leading trend in the genomics market where therapies have the focus on individual genetic profiles. Genomics is being used by hospitals and pharmaceutical companies in developing targeted therapies for cancer and genetic disorders. This approach increases the success rate of treatment and reduces side effects. For this reason, it has become a preferred healthcare solution.
- Increasing Direct-to-Consumer Genetic Testing: Direct-to-consumer genetic testing kits have gained popularity because of increased interest in people's ancestry, health risks, and traits. The two leading companies are 23andMe and AncestryDNA. Such firms offer cheap and easy tests, and the convenience of performing them at home increases public interest and contributes to the growth of this market.
- Growing Adoption of Artificial Intelligence in Genomics: AI is revolutionizing genomics. It analyzes the huge amount of genetic data really fast and correctly. Researchers identify patterns, predict diseases, and develop new treatments with its help. It helps in diagnostics, drug discovery, and personalized medicine. Therefore, it is an important trend in shaping the future of genomics.
Report Scope
Area of Focus |
Details |
Market Size in 2025 |
USD 44.21 Billion |
Expected Market Size in 2034 |
USD 175.18 Billion |
Projected CAGR 2025 to 2034 |
16.53% |
Dominant Region |
North America |
Fastest Growing Region |
Asia-Pacific |
Key Segments |
Technology, Deliverables, Study Type, Application, End-User, Region |
Key Companies |
23andMe, Agilent Technologies, Bio-Rad Laboratories, Eurofins, Roche, GE Healthcare, Illumina, Luminex, Myriad Genetics, Oxford Nanopore Technologies, Pacific Biosciences, PerkinElmer, QIAGEN, Quest Diagnostics, Thermo Fisher Scientific |
Genomics Market Dynamics
Drivers
Increased demand for personalized medicine
- Personalized medicine is, therefore, the largest driver of the genomics market. It emphasizes developing treatments based on the genetic makeup of an individual, making the treatments more effective and with fewer side effects. Therefore, with increasingly more people looking for their treatment to be personal, demand increases for genomics.
Rapid Advancement in Genomic Technologies
- The significant advancements in genomics technologies, particularly those involving Next-generation sequencing tools and gene editors like the CRISPR tool, create great growth paths for the markets. These ensure faster, cheaper, and error-free genetic study. Researchers have been using this to study many diseases, the development of various new treatments for these diseases, and diagnostics. Improving accessibility to any researcher, firms, and direct consumers has speeded up the adoption pace of all market categories.
Restraints
High Cost of Genomics Technologies
- The most significant obstacle in the genomics market is the high costs of technologies that include sequencing, gene editing, and bioinformatics tools. Despite the cost reduction over time, this remains a sizeable initial investment and operation cost for most research institutions, hospitals, and small companies. Access to genomics solutions remains relatively limited in the low-income regions, hence significantly slowing the rate of growth in the adoption and growth of this market.
Sophisticated Ethical and Legal Concerns
- The genomics market faces a multitude of ethical and legal challenges. The issue of privacy, consent in genetic testing, and the possible misuse of genetic information raise a great deal of concern for both the individual and the government. Gene editing also leads to increased regulations on such topics, causing a delay in research and product development in the genomics area.
Opportunities
Advancements in Personalized Medicine
- The genomics market opens up very significant opportunities for personalized medicine. Because of the insight gained into one's genetic makeup, one can design effective treatments for any disease, ranging from cancer and rare genetic disorders, with better patient outcomes with minimal side effects. More and more healthcare delivery systems are going to use this approach; thus, there is going to be an increasing demand for genomics solutions from companies engaged in genetic testing, sequencing, and analysis services.
Increased demand for genomic data in drug development
- The growing number of pharmaceutical companies are focusing on genomic data for new drugs. Genomics helps identify genes that cause the disease and predict responses to drugs. This can lead to a more rapid research cycle and the opportunity for successful clinical trials. All this has allowed genomics companies to partner with the pharmaceutical industry to bring innovation and increase markets.
Challenges
Inadequate access to qualified professionals
- The dearth of skilled professionals is yet another challenge that the genomics market is undergoing. The kind of knowledge necessary for genomic technologies crosses over with bioinformatics, genetics, and molecular biology. This often exceeds supply, which prevents many firms and research establishments from finding manpower to fit these criteria. Genomic discoveries come up slowly because their implementation becomes very slow and unpractical, especially in developing areas without such education facilities.
Regulatory Challenges
- The genomics market is vulnerable to varied and complex regional regulatory standards. The use of genomic data, clinical trials, and gene therapies has a varied approach in different countries. It takes time and becomes expensive for companies to deal with the varied regulations when operating in different markets. The delay in approval or vagueness regarding legal frameworks hampers the development of new genomic products and therapies, affecting the growth of the market.
Genomics Market Segmental Analysis
The genomics market is segmented into technology, deliverables, study type, application, end-User and region. Based on technology, the market is classified into NGS, polymerase chain reaction, microarray, gene editing, flow cytometry, in-situ hybridization and others. Based on deliverables, the market is classified into products and services. Based on study type, the market is classified into functional genomics, biomarker discovery, pathway analysis, epigenomics and others. Based on application, the market is classified into diagnostics, drug discovery and development, agriculture and research and development. Based on end-user, the market is classified into healthcare and diagnostics, pharmaceutical and biotechnology companies, academic and research institutes and agriculture and food industry.
Technology Analysis
Next-Generation Sequencing (NGS): NGS is a disruptive technology that rapidly and inexpensively sequences large DNA or RNA segments. It does whole-genome sequencing, targeted sequencing, and transcriptome analysis. Applications range from cancer research and rare genetic diseases to infectious diseases. Its high processing speed and cost-effectiveness make it the most popular genomics tool.
Polymerase Chain Reaction (PCR): PCR is one of the main genomics tools, which amplifies a small sample of DNA to analyze. This tool is applied for diagnosing infectious diseases, detecting genetic mutations, and analyzing genes. The method is quite common in laboratories since it is easy, fast, and efficient.
Microarray Technology: Microarrays analyze gene expression and genetic variations across thousands of genes simultaneously. They are used in cancer research, pharmacogenomics, and personalized medicine. Microarrays help detect SNPs and copy number variations, vital for disease risk assessments.
Gene Editing (CRISPR): It's a very sharp tool that will cut and edit DNA sequences and modify genes in specific locations, and this tool has transformed the research of genetic diseases, therapies for cancer, and agriculture. For developing gene therapy and increasing crop yields, affordability and versatility in CRISPR are a necessity.
Application Analysis
Diagnostics: Genomic technologies significantly aid in diagnosis, particularly in identifying genetic disorders and cancer as well as infectious diseases. It supports early detection and allows for risk assessment, thereby creating personalized treatment planning by the doctor. Examples are prenatal screenings, hereditary cancer testing, and pharmacogenomics.
Drug Discovery and Development: Genomics speeds up drug research by identifying the genes and proteins causing diseases. This accelerates the production of more effective and safe drugs for pharmaceutical companies. It is also used in predicting the responses of drugs to the body, thereby reducing trial-and-error treatment.
Agriculture: In agriculture, genomics enhances crop productivity and resistance to diseases. It is applied in livestock breeding for improvement in traits such as growth, fertility, and tolerance to diseases. Genomics also helps in the development of GMOs for food security.
Research and Development: The institutes of research and universities use genomics to determine genes, explain the mechanisms behind diseases, and discover new, innovative therapies. This segment enhances genomic tools as well as newer discoveries for health care, agriculture, and biotechnology.
End-Users Analysis
Health care and diagnostics service providers: These consist of hospitals, clinics, and diagnostic labs that can utilize genomic testing in patients to enhance treatment. This also includes cancer diagnosis, genetic disorders, and pharmacogenomic tests for the most effective prescription according to the individual's genetic code.
Pharmaceutical and Biotechnology Companies: These companies use genomics for drug development and personalized medicines. By studying gene functions and mutations, they design therapies targeting specific diseases, such as gene-based treatments for rare genetic disorders.
Genomics Market Share, By End-User, 2024 (%)
End-User |
Revenue Share, 2024 (%) |
Healthcare and Diagnostics |
21% |
Pharmaceutical and Biotechnology Companies |
48% |
Academic and Research Institutes |
7% |
Others |
24% |
Academic and Research Institutes: Universities and research organizations use genomics for various studies, such as discovering disease-causing genes and exploring gene-environment interactions. These institutions are pivotal in advancing genomics knowledge and its practical applications.
Agriculture and Food Industry: Companies in this sector use genomics to breed plants with better yields and livestock with improved health and productivity. Genomics also ensures food safety by identifying genetic markers for contamination or allergenic risks.
Genomics Market Regional Analysis
The genomics market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:
North America: The North America genomics market size was valued at USD 16.12 billion in 2024 and is expected to reach around USD 74.45 billion by 2034. North America is the largest genomics market because of its advanced healthcare infrastructure, leading research institutions, and high adoption rates of genomic technologies. The U.S. is a hub for innovations like NGS and gene editing, with strong government funding for genomic research.

Europe: The Europe genomics market size was estimated at USD 10.51 billion in 2024 and is reported around USD 48.52 billion by 2034. The genomics market is growing steadily in Europe, driven by investments made by countries like Germany, the UK, and France in genomic research and personalized medicine. Here, the emphasis is on genetic testing for diseases like cancer and projects such as the UK's 100,000 Genomes Project.
Asia-Pacific: The Asia-Pacific genomics market size was surpassed at USD 9.64 billion in 2024 and is forecasted to hit around USD 44.50 billion by 2034. The growth in this region is due to investments in healthcare and awareness of genomic medicine. The countries of China and India are building their genomics infrastructure and focus on genetic testing, agricultural genomics, and research collaborations.

LAMEA: The LAMEA genomics market size was reached at USD 1.67 billion in 2024 and is predicted to grow around USD 7.71 billion by 2034. For its part, regions like Latin America, the Middle East, and Africa are where this industry is at an embryonic state. Nevertheless, awareness about diagnostic genomics continues to rise alongside greater advancements in healthcare centers. The latter factors continue propelling the requirements for better study in these areas while conducting genetic analysis.
Genomics Market Top Companies
- 23andMe
- Agilent Technologies
- Bio-Rad Laboratories
- Eurofins
- Roche
- GE Healthcare
- Illumina
- Luminex
- Myriad Genetics
- Oxford Nanopore Technologies
- Pacific Biosciences
- PerkinElmer
- QIAGEN
- Quest Diagnostics
- Thermo Fisher Scientific
Recent Developments
- In January 2025, Genetic Technologies Limited (GTG) has finalized the sale of its direct-to-consumer DNA testing businesses, AffinityDNA and EasyDNA, to Endeavor DNA, Inc. on January 18, 2025. The transaction was valued at approximately $525,000 and included the transfer of intellectual property, agreements, and employees to Endeavor DNA.
- In January 2025, Clear Labs secured $60 million in funding to advance its nanopore sequencing technology, which is expected to enhance genomic research capabilities and applications in healthcare.
- In January 2025, Genomics England announced plans to sequence 100,000 newborns to advance genomic research and improve healthcare outcomes. This initiative highlights the growing importance of genomic data in understanding genetic disorders and personalizing treatments.
Market Segmentation
By Technology
- Next-Generation Sequencing (NGS)
- Polymerase Chain Reaction (PCR)
- Microarray
- Gene Editing
- Flow Cytometry
- In-Situ Hybridization
- Others
By Deliverables
- Products
- Instruments/Systems/Software
- Consumables & Reagents
- Services
- NGS-based Services
- Core Genomics Services
- Biomarker Translation Services
- Computational Services
- Others
By Study Type
- Functional Genomics
- Biomarker Discovery
- Pathway Analysis
- Epigenomics
- Others
By Application
- Diagnostics
- Drug Discovery and Development
- Agriculture
- Research and Development
By End-User
- Healthcare and Diagnostics
- Pharmaceutical and Biotechnology Companies
- Academic and Research Institutes
- Agriculture and Food Industry
By Region
- North America
- Europe
- Asia-Pacific
- LAMEA
...
...